| Bioactivity | SSTR5 Antagonist 1 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of treat type 2 diabetes mellitus (T2DM)[1]. |
| Target | SSTR5. |
| In Vivo | SSTR5 antagonist 2 (10 mg/kg, orally) increases both total and active circulating incretin hormone GLP1 levels in mice at a dose of 10 mg/kg[1].SSTR5 antagonist 2 increases pancreatic insulin secretion as well as total and active GLP1 release, and demonstrates synergistic effects in combination with DPP4 inhibitors[1]. Animal Model: |
| Name | SSTR5 antagonist 2 TFA |
| CAS | 1254733-98-6 |
| Formula | C34H36F4N2O7 |
| Molar Mass | 660.65 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Liu W, et al. Discovery and Pharmacology of a Novel Somatostatin Subtype 5 (SSTR5) Antagonist: Synergy with DPP-4 Inhibition. ACS Med Chem Lett. 2018 Sep 12;9(11):1082-1087. |
SSTR5 antagonist 2 TFA
CAS: 1254733-98-6 F: C34H36F4N2O7 W: 660.65
SSTR5 Antagonist 1 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5)
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.